MENLO PARK, Calif., May 22, 2017 -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a leading gene therapy company advancing novel medicines to address unmet needs in serious rare and ocular diseases, announced today that Amber Salzman, Ph.D., president and chief executive officer, will present at the Jefferies Global Healthcare Conference.
| Event: | Jefferies Global Healthcare Conference |
| Date: | June 7, 2017 |
| Time: | 1:30 – 2:00 p.m. ET |
| Location: | New York, NY |
A live and replay video webcast of the presentation will be available from Adverum’s website at http://investors.adverum.com.
About Adverum Biotechnologies, Inc.
Adverum is a gene therapy company advancing novel medicines that can offer life-changing benefits to patients living with serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat wet age-related macular degeneration (wAMD) and rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, the Company generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum’s core capabilities include clinical development and in-house manufacturing expertise, specifically in process development and assay development. For more information please visit www.adverum.com.
Contacts for Adverum: Leone Patterson Chief Financial Officer Adverum Biotechnologies, Inc. 650-665-7222 [email protected] Tricia Truehart Vice President The Trout Group LLC 646-378-2953 [email protected]


Boeing Posts Fourth-Quarter Profit on Jeppesen Sale Despite Ongoing Unit Losses
First Abu Dhabi Bank Reports 22% Jump in Q4 Profit, Beats Market Expectations
Elon Musk Reportedly Eyes June 2026 SpaceX IPO Timed With Planetary Alignment and Birthday
The Maire - EuroChem Case: Three Lessons for Global Business
Anthropic Raises 2026 Revenue Outlook by 20% but Delays Path to Profitability
Meta Stock Surges After Q4 2025 Earnings Beat and Strong Q1 2026 Revenue Outlook Despite Higher Capex
China Approves First Import Batch of Nvidia H200 AI Chips Amid Strategic Shift
Volkswagen CEO Oliver Blume Faces Crucial Year as Investors Demand Turnaround Results
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold
Ford and GM Near Financing Deal to Support First Brands Group During Bankruptcy
NVIDIA, Microsoft, and Amazon Eye Massive OpenAI Investment Amid $100B Funding Push
C3.ai in Merger Talks With Automation Anywhere as AI Software Industry Sees Consolidation
Google Disrupts Major Residential Proxy Network IPIDEA
Alibaba-Backed Moonshot AI Unveils Kimi K2.5 to Challenge China’s AI Rivals
Puma’s Historic Rivalry With Adidas Enters a New Era as Anta Deal Signals Turnaround Push
ASML’s EUV Lithography Machines Power Europe’s Most Valuable Tech Company 



